Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin  by Maraha, B. et al.
CONCISE COMMUNICATION
Decolonization of methicillin-resistant Staphylococcus aureus using oral
vancomycin and topical mupirocin
B. Maraha1, J. van Halteren2, J. M. Verzijl3, R. G. F. Wintermans4 and A. G. M. Buiting1
1Department of Medical Microbiology, 2Department of Hospital Hygiene and Infection Control, St.
Elisabeth Hospital, PO Box 747, 5000 AS Tilburg, 3Hospital Pharmacy Midden-Brabant, St. Elisabeth
Hospital and TweeSteden Hospital, Tilburg, and 4Department of Medical Microbiology, Franciscus
Hospital, Roosendaal, the Netherlands
The objective of this study was to assess the efﬁcacy and safety of a short course of oral
vancomycin and intranasal mupirocin ointment in the eradication of methicillin-resistant
Staphylococcus aureus (MRSA) colonization. During an outbreak of MRSA, the colonized
subjects received oral vancomycin and topical mupirocin. They were screened for MRSA
1, 3, 6 and 12months after decolonization. A questionnaire was developed to evaluate the
side-effects of oral vancomycin. Thirty-ﬁve subjects were treated. Clearance was
achieved in all cases, in 24 (69%) subjects after one course of therapy. Twenty-eight
(80%) subjects experienced some side-effects, including six (17%) who did not tolerate
oral vancomycin. Although oral vancomycin, in combination with topical mupirocin, is
effective in the elimination of MRSA colonization, there is a need for further studies to
conﬁrm our results and to evaluate the safety of oral vancomycin.
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INTRODUCTION
Control measures are essential to limit and prevent
the spread of methicillin-resistant Staphylococcus
aureus (MRSA) in outbreaks. These measures may
include isolation of patients withMRSA, screening
of contact patients and staff, and temporary
removal of colonized staff from themedical setting
[1]. It has been emphasized that eradication of
MRSA carriage is justiﬁed in outbreak situations
in health-care settings [1,2]. Several eradication
regimens have been used. Topical agents alone
or in combination with oral antibiotics have been
used for the elimination of both nasal and extra-
nasal MRSA carriage [3–10]. Intranasal application
of mupirocin seems to be the most effective topical
agent for the eradication of MRSA nasal carriage
[11–13]. Relapse and recolonization, however, are
frequently reported, and clearance rates have often
been unsatisfactory [1]. Several hospitals in the
Netherlands use oral vancomycin in combination
with topical agents for the eradication of MRSA
colonization. There are, however, no data available
on the effectiveness and safety of eradication regi-
mens with oral vancomycin.
Oral vancomycin has been successfully used in
the treatment of postoperativeMRSA enteritis [14].
Few data are available, however, on the use and
the efﬁcacy of vancomycin for eradicating the
carriage ofMRSA. In one study, topical application
of 5% vancomycin for 2weeks was successfully
used to eradicate MRSA nasal carriage in two
nurses [4]. In another study, vancomycin ointment
failed to eradicate nasal carriage of methicillin-
sensitive staphylococci [15]. In two case reports,
decolonization of nasopharyngeal MRSA coloni-
zation was achieved using a vancomycin aerosol
[16,17].
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Oral vancomycin is used for treating Clostridium
difﬁcile-associated infection [18]. It has been
reported that oral vancomycin is safe and
well-tolerated in the context of C. difﬁcile infection
[19–23].
During an outbreak of MRSA at our hospital
and in a nursing home in our region, we evaluated
the efﬁcacy and tolerance of a short course of oral
vancomycin and topical intranasal mupirocin in
the eradication of MRSA colonization.
MATERIALS AND METHODS
The index patient in this outbreak was a patient
admitted, in January 1999, to the Urological Unit in
our hospital from a nursing home in our region.
This patient had a wound infected with MRSA
which was resistant to ciproﬂoxacin in addition to
b-lactam antibiotics. It was susceptible to mupir-
ocin, cotrimoxazole, rifampin, gentamicin, tobra-
mycin, and vancomycin.
Surveillance cultures were obtained from all
patients and staff of the Urological Unit and from
staff from other units who had been in contact with
the index patient. Also, all residents and staff of the
nursing home where the index patient was living
were screened. Culture specimens were obtained
by sterile swabs twice from anterior nares, throat,
perineum, and wounds if any. The swabs were
cultured on sheep blood agar plates and mannitol
salt agar plates containing 7.5% NaCl and 4mg/L
oxacillin [24]. To increase the sensitivity of MRSA
detection, we used a staphylococcal broth contain-
ing Muller–Hinton II broth (Becton Dickinson,
Cockeysville, MD, USA) and ciproﬂoxacin 8mg/
L (Bayer, Leverkusen, Germany). In the ﬁrst
screening, all three swabs were put into the same
staphylococcal broth [25]. Subsequently, in sub-
jects with a positive culture, each swab was put
into a separate staphylococcal broth. Plates and
broth were incubated at 35 8C in air. At 24 h, plates
were examined and broth was subcultured on a
sheep blood agar plate and on an agar screen plate
containing 6mg/L oxacillin; plates were again
incubated at 35 8C. Plates were examined again
at 24 h and 48 h. Colonies suspected of being
S. aureus were identiﬁed by standard procedures,
including colony morphology, Gram stain, cata-
lase reaction, tube coagulase test, and API STAPH
(bioMe´rieux sa, Lyon, France) [26].
Susceptibility testing of S. aureus isolates was
carried out by a broth microdilution method
according to the guidelines of the National Com-
mittee for Clinical Laboratory Standards [27].
Methicillin resistance was determined by oxacillin
disk diffusion test and by oxacillin E test [24,28].
Isolates were conﬁrmed to be methicillin resistant
by polymerase chain reaction (PCR) for the mecA
gene [29]. Phage typing was performed at the
National Institute of Public Health and the Envir-
onment.
The index patient and the colonized residents
were strictly isolated in private rooms, at hospital
and in the nursing home, respectively. Adminis-
tration of medication, if any, and diagnostic pro-
cedures were carried out in the private room,
when possible. Barriers including gloves, masks,
head caps and aprons were used for any contact
with the index patient and colonized residents.
The importance of washing hands with 70% alco-
hol after each contact was emphasized. Colonized
staff were not allowed to work until they were
decolonized.
Subjects who were colonized with MRSA
received a 5-day course of oral vancomycin
250mg every 6 h (Vancomycin CP1, 83.3mg/
mL; 120mL, Eli Lilly, Indianapolis, IN,), intranasal
application of mupirocin every 8 h (Bactroban1
nasal ointment 20mg/mL; 3 g tubes. SmithKline
Beecham Farma, Brentford, UK), and a daily bath
with povidone–iodine shampoo (Betadine1 sham-
poo, 75mg/mL, Asta Medica, Frankfurt/Main,
Germany). This course was repeated when neces-
sary. The index patient did not undergo the deco-
lonization regimen, because she had many
wounds infected with MRSA. The four colonized
residents were decolonized.
Decolonization of MRSA was deﬁned by two
consecutive negative swabs 5 and 14 days follow-
ing treatment. Follow-up cultures were obtained 1,
3, 6 and 12months after decolonization.
When oral vancomycin was not tolerated and
the side-effects were very serious, treatment with
oral vancomycin was discontinued and an alter-
native regimen was undertaken. A questionnaire
was developed to evaluate the side-effects of oral
vancomycin in all subjects. Following treatment
completion and when MRSA eradication was
achieved, the 35 colonized subjects received a
questionnaire to assess on a scale of 1–10 (1: no
effect; and 10: severe) the side-effects they experi-
enced from oral vancomycin. Evidence of skin and
soft tissue infections was monitored in all colo-
nized subjects.
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RESULTS
In all, 360 staff and 274 patients and residents of
the nursing home were screened for MRSA colo-
nization. Thirty-ﬁve subjects were colonized with
MRSA; 31 staff and four residents of the nursing
home. The PCR assay showed that all isolated
strains possessed the mecA gene. The strains from
the 35 subjects belonged to phage type Z-151. Six
subjects were colonized in the nares, the throat and
the perineum; three subjects in the nares and the
throat; four subjects in the nares and two subjects
in the throat. In 20 subjects, it was not possible to
discriminate between the colonized body sites,
because in these subjects MRSA was detected only
in the ﬁrst screening, in which the three swabs
were put into the same staphylococcal broth. None
of the colonized residents of the nursing home or
of the staff had infection with MRSA. The index
patient was not included in the analysis because
she was infected with MRSA. The mean follow-up
period of the study population was 241 days
(range 180–365 days).
The 35 colonized subjects received 55 therapy
courses, with a mean of 1.6 (SD 0.9) courses per
subject. MRSA clearance was achieved in all sub-
jects; in 24 (69%) subjects after one course of
therapy. In 11 subjects, more than one course
was needed for decolonization (Table 1).
The response rate of the questionnaire was
100%. Twenty-eight (80%) subjects experienced
side-effects from oral vancomycin (Table 2). The
seriousness of the side-effects in these 28 subjects
ranged from 1 to 10 (mean 4.6, SD 3.0). Of the 28
subjects with side-effects, six reported the side-
effects as severe, whereas the remaining 22 sub-
jects found that the side-effects could be tolerated.
Oral vancomycin was not tolerated by 17% (6/35)
of the subjects. In these subjects, oral vancomycin
was discontinued and oral cotrimoxazole, 960mg
every 12 h, and oral rifampin, 600mg every 12 h,
were given for 5 days. However, two of these six
subjects did not tolerate cotrimoxazole and rifam-
pin either; so oral tobramycin, 80mg every 6 h, for
5 days was substituted.
DISCUSSION
This study shows the efﬁcacy of the combination of
oral vancomycin, topical intranasal mupirocin,
and a bath with povidone–iodine shampoo in
eliminating MRSA colonization. Oral vancomycin
was not tolerated by 17% of the subjects.
Eradicating regimens containing oral vancomy-
cin are used in several hospitals in the Netherlands
to eliminate extranasal colonization with MRSA.
This is the ﬁrst study, that assesses the efﬁcacy of
oral vancomycin in the elimination of MRSA colo-
nization. Our approach included screening of
patients, residents and staff, strict isolation of
the colonized patient and the nursing home resi-
dents, and treatment of all colonized subjects. This
approach was very effective in the elimination of
MRSA colonization during an outbreak at our
hospital and in a nursing home. We succeeded
in eradicating MRSA colonization in 100% of the
colonized subjects, and all subjects were still
MRSA-free after a follow-up period ranging from
180 to 365days (mean 241 days).
Various topical and oral agents have been used
to eradicate MRSA colonization, and variable
clearance rates have been achieved. In general,
Table 1 Courses of treatment
Eradication course No. of subjects
Aa 24
2A 3
3A 2
2AþBb 4
AþBþCc 1
Aþ 2BþC 1
aA, oral vancomycin 250mg every 6 h, nasal application of
mupirocin ointment every 8 h, and a daily bath with
povidone–iodine shampoo, for 5 days.
bB, as in A, but oral vancomycin was replaced by oral
cotrimoxazole 960mg every 12 h plus rifampin 600mg
every 12 h.
cC, as for A but oral vancomycin was replaced with oral
tobramycin 80mg every 6 h.
Table 2 Side-effects experienced by the study subjectsa
Side-effect No. of subjects (%)
None 7 (20)
Dry mouth 10 (29)
Unpleasant taste 16 (46)
Stomatitis 6 (17)
Nausea 6 (17)
Abdominal pain 6 (17)
Diarrhoea 21 (60)
Flatus 4 (11)
aTwenty-eight subjects experienced more than one side-
effect.
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the results have been unsatisfactory, and relapse
and recolonization have been reported [1].
Because the care staff colonized with MRSA are
an important source of MRSA spread, it has been
advocated that attempts should be made to deco-
lonize them [13]. The prevalence of MRSA in the
Netherlands is still very low (<0.5%) and this
reﬂects the Dutch policy of ‘search and destroy’
which includes strict control measures and the
treatment of MRSA carriage [30]. In this context,
we treated the study subjects regardless of the
colonized body site. In the present outbreak, dis-
crimination between the colonized body sites was
possible in 15 subjects. In the remaining 20 sub-
jects, this was not possible because the swabs from
different sites were pooled in the ﬁrst screening.
The study subjects reported no local irritation as
a side-effect; therefore, the reported side-effects
could not be attributed to topical mupirocin. In
addition, other studies have shown that topical
mupirocin is safe and well-tolerated [5,7,12]. Pre-
vious studies reported that eradication regimens
with systemic rifampin, cotrimoxazole and cipro-
ﬂoxacin are associated with side-effects [7,8]. In
the context of the treatment of C. difﬁcile infection,
no side-effects of oral vancomycin have been
reported [19–23]. However, subjects in the present
study were healthy, and patients with C. difﬁcile
infection have gastrointestinal complaints. Gastro-
intestinal side-effects were predominant in the
present study. Therefore, side-effects of oral van-
comycin in patients treated for C. difﬁcile infection
might be confused with those attributable to the
C. difﬁcile infection.
Administration of vancomycin has been asso-
ciated with the emergence of resistant bacteria
[31]. However, a meta-analysis of 18 studies has
shown that, in contrast to intravenous vancomy-
cin, oral vancomycin contributes in a limited way
to the overall risk of vancomycin-resistant enter-
ococcus colonization [31]. This reﬂects the limited
use of oral vancomycin. A limitation of the present
study, however, is that we did not evaluate the
impact of vancomycin use on emergence of van-
comycin-resistant enterococcus in the study sub-
jects. Because of the consequences of excessive use
of vancomycin, it is probably undesirable to use
this antibiotic in all colonized patients. One might
use oral vancomycin only in patients with diges-
tive tract colonization.
In conclusion, the combination of oral vanco-
mycin and topical agents is effective in the
elimination of MRSA colonization. There is a
need for further assessment of efﬁcacy and safety
of oral vancomycin in randomized controlled
trials.
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